Michael Pourdehnad
Assistant Clinical Professor
Medicine
School of Medicine

Publications (37)

Top publication keywords:
TOR Serine-Threonine KinasesLymphoma, Non-HodgkinProtein BiosynthesisAcetamidesProto-Oncogene Proteins c-mycQuinazolinonesUbiquitin-Protein LigasesFluorodeoxyglucose F18Lymphoma, Large B-Cell, DiffuseAdaptor Proteins, Signal TransducingTomography, Emission-ComputedAntineoplastic AgentsPiperidonesBenzoxazolesIsoindoles

• Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC-92480), a novel cereblon E3 ligase modulator.
  CPT: pharmacometrics & systems pharmacology 2023 Wu F, Liu L, Gaudy A, Wang X, Carayannopoulos L, Pourdehnad M, Lamba M
• Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
  The New England journal of medicine 2023 Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ, Ramasamy K, Martinez-Lopez J, Quach H, Orlowski RZ, Arnao M, Lonial S, Karanes C, Pawlyn C, Kim K, Oriol A, Berdeja JG, Rodríguez Otero P, …
• Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.
  EJHaem 2022 Nastoupil LJ, Kuruvilla J, Chavez JC, Bijou F, Witzig TE, Santoro A, Flinn IW, Boccomini C, Kenkre VP, Corradini P, Isufi I, Andorsky DJ, Klein LM, Greenwald DR, Sangha R, Shen F, Hagner P, Li Y, …
• Correction to: Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.
  The AAPS journal 2022 Abbiati RA, Pourdehnad M, Carrancio S, Pierce DW, Kasibhatla S, McConnell M, Trotter MWB, Loos R, Santini CC, Ratushny AV
• Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
  EJHaem 2022 Ribrag V, Chavez JC, Boccomini C, Kaplan J, Chandler JC, Santoro A, Corradini P, Flinn IW, Advani R, Cassier PA, Sangha R, Kenkre VP, Isufi I, Uttamsingh S, Hagner PR, Gandhi AK, Shen F, Michelliza S,…

Show all (32 more) Hide

• Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.
  The AAPS journal 2021 Abbiati RA, Pourdehnad M, Carrancio S, Pierce DW, Kasibhatla S, McConnell M, Trotter MWB, Loos R, Santini CC, Ratushny AV
• Population Pharmacokinetics of CC-122.
  Clinical pharmacology : advances and applications 2021 Cheng Y, Chen J, Pourdehnad M, Zhou S, Li Y
• CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.
  Journal of medicinal chemistry 2021 Hansen JD, Correa M, Alexander M, Nagy M, Huang D, Sapienza J, Lu G, LeBrun LA, Cathers BE, Zhang W, Tang Y, Ammirante M, Narla RK, Piccotti JR, Pourdehnad M, Lopez-Girona A
• CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
  Blood 2021 Surka C, Jin L, Mbong N, Lu CC, Jang IS, Rychak E, Mendy D, Clayton T, Tindall E, Hsu C, Fontanillo C, Tran E, Contreras A, Ng SWK, Matyskiela M, Wang K, Chamberlain P, Cathers B, Carmichael J, Hansen…
• Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies.
  Cancer science 2020 Hatake K, Chou T, Doi T, Terui Y, Kato H, Hirose T, Seo S, Pourdehnad M, Ogaki Y, Fujimoto H, Hagner PR, Yamamoto K
• Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
  The Lancet. Haematology 2020 Michot JM, Bouabdallah R, Vitolo U, Doorduijn JK, Salles G, Chiappella A, Zinzani PL, Bijou F, Kersten MJ, Sarmiento R, Mosulen S, Mendez C, Uttamsingh S, Pourdehnad M, Hege K, Chen T, Klein C, Hagner…
• Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
  Blood 2020 Carpio C, Bouabdallah R, Ysebaert L, Sancho JM, Salles G, Cordoba R, Pinto A, Gharibo M, Rasco D, Panizo C, Lopez-Martin JA, Santoro A, Salar A, Damian S, Martin A, Verhoef G, Van den Neste E, Wang M,…
• Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent.
  Blood 2020 Risueño A, Hagner PR, Towfic F, Fontanillo C, Djebbari A, Parker JS, Drew CP, Nowakowski GS, Maurer MJ, Cerhan JR, Wei X, Ren Y, Lee CW, Couto S, Wang M, Pourdehnad M, Gandhi AK, Trotter MWB
• A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Rasco DW, Papadopoulos KP, Pourdehnad M, Gandhi AK, Hagner PR, Li Y, Wei X, Chopra R, Hege K, DiMartino J, Shih K
• CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
  Blood 2015 Hagner PR, Man HW, Fontanillo C, Wang M, Couto S, Breider M, Bjorklund C, Havens CG, Lu G, Rychak E, Raymon H, Narla RK, Barnes L, Khambatta G, Chiu H, Kosek J, Kang J, Amantangelo MD, Waldman M, …
• Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers.
  Proceedings of the National Academy of Sciences of the United States of America 2013 Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D
• Investigating Myc-dependent translational regulation in normal and cancer cells.
  Methods in molecular biology (Clifton, N.J.) 2013 Cunningham JT, Pourdehnad M, Stumpf CR, Ruggero D
• Reduced grey matter metabolism due to white matter edema allows optimal assessment of brain tumors on 18F-FDG-PET.
  Hellenic journal of nuclear medicine 2011 Pourdehnad M, Basu S, Duarte P, Okpaku AS, Saboury B, Hustinx R, Alavi A
• Stability of cerebral blood flow measures using a split-dose technique with (99m)Tc-exametazime SPECT.
  Nuclear medicine communications 2005 Newberg AB, Saffer J, Farrar J, Pourdehnad M, Alavi A
• 18F-FDG PET in malignant lymphoma: significance of positive findings.
  European journal of nuclear medicine and molecular imaging 2005 Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, Battista G, Tani M, Stefoni V, Canini R, Monetti N, Rubello D, Alavi A, Franchi R, Fanti S
• PET imaging for differentiating recurrent brain tumor from radiation necrosis.
  Radiologic clinics of North America 2005 Hustinx R, Pourdehnad M, Kaschten B, Alavi A
• Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery.
  Journal of neuro-oncology 2004 Mamot C, Nguyen JB, Pourdehnad M, Hadaczek P, Saito R, Bringas JR, Drummond DC, Hong K, Kirpotin DB, McKnight T, Berger MS, Park JW, Bankiewicz KS
• Synthesis and evaluation of fluorine-18 labeled glyburide analogs as beta-cell imaging agents.
  Nuclear medicine and biology 2004 Schmitz A, Shiue CY, Feng Q, Shiue GG, Deng S, Pourdehnad MT, Schirrmacher R, Vatamaniuk M, Doliba N, Matschinsky F, Wolf B, Rösch F, Naji A, Alavi AA
• Cerebral blood flow during meditative prayer: preliminary findings and methodological issues.
  Perceptual and motor skills 2003 Newberg A, Pourdehnad M, Alavi A, d'Aquili EG
• Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders?
  Nuclear medicine communications 2001 Zhuang HM, Cortés-Blanco A, Pourdehnad M, Adam LE, Yamamoto AJ, Martínez-Lázaro R, Lee JH, Loman JC, Rossman MD, Alavi A
• Inter-modality comparisons of seizure focus lateralization in complex partial seizures.
  European journal of nuclear medicine 2001 Meyer PT, Cortés-Blanco A, Pourdehnad M, Levy-Reis I, Desiderio L, Jang S, Alavi A
• Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001 Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, Mozley PD, Rossman MD, Albelda SM, Alavi A
• Similar pelvic abnormalities on FDG positron emission tomography of different origins.
  Clinical nuclear medicine 2001 Zhuang H, Yamamoto AJ, Sinha P, Pourdehnad M, Liu Y, Alavi A
• Intense F-18 fluorodeoxyglucose uptake caused by mycobacterium avium intracellulare infection.
  Clinical nuclear medicine 2001 Zhuang H, Pourdehnad M, Yamamoto AJ, Rossman MD, Alavi A
• The measurement of regional cerebral blood flow during the complex cognitive task of meditation: a preliminary SPECT study.
  Psychiatry research 2001 Newberg A, Alavi A, Baime M, Pourdehnad M, Santanna J, d'Aquili E
• The promising role of 18F-FDG PET in detecting infected lower limb prosthesis implants.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001 Zhuang H, Duarte PS, Pourdehnad M, Maes A, Van Acker F, Shnier D, Garino JP, Fitzgerald RH, Alavi A
• The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver.
  Nuclear medicine communications 2000 Zhuang H, Sinha P, Pourdehnad M, Duarte PS, Yamamoto AJ, Alavi A
• 26. Incidental findings should be included in the analysis of cost-effectiveness for evaluation of pulmonary nodules by FDG-PET.
  Clinical positron imaging : official journal of the Institute for Clinical P.E.T 2000 Zhuang HM, Duarte P, Pourdehnad M, Yamamoto AJ, Loman JC, Sinha P, Alavi A
• Gastric emptying of solids: estimates of lag phase and constant emptying times.
  Nuclear medicine communications 2000 Couturier O, Le Rest C, Gournay J, Pourdehnad M, Bridji B, Turzo A, Bizais Y
• Standardized uptake value as an unreliable index of renal disease on fluorodeoxyglucose PET imaging.
  Clinical nuclear medicine 2000 Zhuang H, Duarte PS, Pourdehnad M, Li P, Alavi A
• Muscarinic blockade inhibits gastric emptying of mixed-nutrient meal: effects of weight and gender.
  The American journal of physiology 1999 Teff KL, Alavi A, Chen J, Pourdehnad M, Townsend RR
• Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: implications for adoptive cell therapy of cancer.
  International journal of oncology 1999 Cesano A, Wortman JA, Pourdehnad M, Visonneau S, Mozley D, Bhatnagar A, Alavi A, Santoli D